ClinicalTrials.gov
public full text
Public Domain
Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors
This is an open-label, dose-escalation/de-escalation study of ARQ 197 administered orally in combination with gemcitabine. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of ARQ 197 when administered in combination with gemcitabine to patients with advanced solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer#994866
- ARQ 197 in Subjects With Metastatic Solid Tumors#967030
- Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors#878415
- A Phase 1 Study of ARQ 197 in Patients With Solid Tumors#917119
- Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer#849412
Record · ID 859236
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive